Roche-ImmunoGen's breast cancer drug Kadcyla wins EU nod

The European Commission has approved Roche and ImmunoGen's Kadcyla, or trastuzumab emtansine, as a treatment for HER-2 positive metastatic breast cancer. The approval was based on data from a late-stage trial that showed Kadcyla improved overall survival, compared with standard therapy. Based on the approval, Roche will pay ImmunoGen a $5 million milestone fee.

View Full Article in:

Medscape (free registration) · Wall Street Journal (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC